SCHEMBL2880209

SCHEMBL2880209

CN(C)C1CCN(Cc2ccc(Cn3cnc4c(F)cccc43)cc2)C1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.49
LTA4H P09960 1/20 0.44
MAP4K4 O95819 2/20 0.42
JAK2 O60674 1/20 0.41
HRH1 P35367 2/20 0.40
KCNH2 Q12809 2/20 0.40
CYP2D6 P10635 1/20 0.40
GRM2 Q14416 1/20 0.39
DDR1 Q08345 1/20 0.39
HDAC1 Q13547 1/20 0.38
SCN8A Q9UQD0 2/20 0.38
CHRM1 P11229 1/20 0.38
SCN1A P35498 1/20 0.38
MELK Q14680 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MITF O75030 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4792995 0.84 LTA4H (0.37) HRH3LTA4HDDR1KDM4E
SCHEMBL2881395 0.83 HRH3 (0.73) HRH3
SCHEMBL2884152 0.80 HRH3 (0.48) HRH3L3MBTL1
SCHEMBL2883883 0.79 HRH3 (0.52) HRH3LTA4HMAP4K4HRH1KCNH2
SCHEMBL2886675 0.79 HRH3 (0.52) HRH3LTA4HMAP4K4HRH1KCNH2
SCHEMBL2881480 0.77 HRH3 (0.60) HRH3
SCHEMBL2881324 0.75 HRH3 (0.52) HRH3LTA4HMAP4K4HRH1KCNH2
SCHEMBL3665676 0.75 HRH3 (0.75) HRH3KCNH2CYP2D6
SCHEMBL3665673 0.75 HRH3 (0.75) HRH3KCNH2CYP2D6
SCHEMBL3729154 0.74 HRH3 (0.67) HRH3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820825-B2 N-substituted-azacyclylamines as histamine-3 antagonists WYETH LLC (US) 2010-10-26 US claimed
EP-1994022-A2 N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS Wyeth a Corporation of the State of Delaware (US) 2008-11-26 EP claimed
WO-2007108936-A2 N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2007-09-27 WO claimed
US-20070219240-A1 N-substituted-azacyclylamines as histamine-3 antagonists WYETH (US) 2007-09-20 US claimed
US-7820825-B2 N-substituted-azacyclylamines as histamine-3 antagonists WYETH LLC (US) 2010-10-26 US disclosed
EP-1994022-A2 N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS Wyeth a Corporation of the State of Delaware (US) 2008-11-26 EP disclosed
WO-2007108936-A2 N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2007-09-27 WO disclosed
US-20070219240-A1 N-substituted-azacyclylamines as histamine-3 antagonists WYETH (US) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219240-A1 N-substituted-azacyclylamines as histamine-3 antagonists HNMT, HRH4, HRH3 HRH3 3/4885LTA4H 457/4885MAP4K4 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.